denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: an educational grant from Novo Nordisk Inc. This continuing medical education activity is provided by Vindico Medical Education.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Bleeding Disorders, Hemophilia, sickle cell disease, Biological, Diseases, Therapies, Hemoglobinopathies, Clinically relevant
Hematology Disease Topics & Pathways:
Bleeding Disorders, Hemophilia, sickle cell disease, Biological, Diseases, Therapies, Hemoglobinopathies, Clinically relevant
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Steven W. Pipe, MD, University of Michigan, University of Michigan
Disclosures:
Pipe: HEMA Biologics: Consultancy, Other; CSL Behring: Consultancy; Catalyst Biosciences: Consultancy; BioMarin: Consultancy, Other: Contracted Research; Bayer: Consultancy, Other: Contracted Research; ApcinteX: Consultancy; Sanofi Genzyme: Consultancy, Other; Spark Therapeutics: Consultancy; Takeda: Consultancy; Siemens: Other; Pfizer: Consultancy; Freeline Therapeutics: Consultancy, Other: Contracted Research; Novo Nordisk: Consultancy, Other: Contracted Research; Roche/Genentech: Consultancy, Other: Contracted Research; Sangamo Therapeutics: Consultancy; uniQure: Consultancy, Other.
Speakers:
Mark Reding, MD, University of Minnesota Medical Center
,
Christine Guelcher, Hemostasis RN-BC, MS, PPCNP-BC, Center for Cancer and Blood Disorders
and
Biree Andemariam, MD, University of Connecticut
Disclosures:
Reding: Takeda: Consultancy, Honoraria, Speakers Bureau; Novo Nordisk: Consultancy, Honoraria, Speakers Bureau; Sanofi Genzyme: Consultancy, Honoraria, Speakers Bureau; BioMarin: Research Funding; Bayer: Consultancy, Honoraria, Research Funding, Speakers Bureau. Guelcher: Takeda: Consultancy; Novo-Nordisk: Consultancy; Octapharma: Consultancy; Genentech, Octapharma, CSL Behring, Takeda, Pfizer, Novo Nordisk: Consultancy. Andemariam: bluebird bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Emmaus: Membership on an entity's Board of Directors or advisory committees; Vertex: Honoraria; Imara: Research Funding; Hemanext: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; NovoNordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Terumo BCT: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Guidepoint: Honoraria; Accordant: Membership on an entity's Board of Directors or advisory committees; CHNCT: Consultancy; CRISPR/Vertex: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cyclerion: Consultancy, Membership on an entity's Board of Directors or advisory committees.
This continuing medical education symposium will address continuing and emerging educational needs in the care and management of patients with sickle cell disease or hemophilia. Experts in the field will provide didactic presentations and panel discussion on these rare non-malignant blood orders to address the tremendous burden of disease that occurs in these patients and provide guidance to integrate current and emerging management strategies into the clinic to enhance patient care and quality of life. The safety and efficacy of recent therapeutic advances will also be evaluated to provide insight into their integration into the treatment decision process and to ensure optimal, individualized patient care.
See more of: Satellite Symposia